EUVIMEDEUVIMED entdecken
Open Access

Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality

Natalia M Sutherland, Baijun Zhou, Lingxiao Zhang, Mei-Sing Ong, Joseph S Hong, Andrew Pak, Katherine J Liu, Matthew J Frigault, Marcela V Maus, Joshua A Hill, Kerry Reynolds, Jolan E Walter und 2 weitere

Journal of Allergy and Clinical Immunology · 2025-02 · 155 (2) · 605-615

DOI: 10.1016/j.jaci.2024.10.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-02. Verfasst von Natalia M Sutherland und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital, Boston, Mass. Hauptthemen laut MEDLINE: Agammaglobulinemia, Antigens, CD19, Immunotherapy, Adoptive, Infections. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIAID, American Academy of Allergy Asthma and Immunology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: CD19-targeted chimeric antigen receptor T-cell therapy (CAR-T therapy) has revolutionized the treatment of hematologic malignancies. As these cells target CD19+ receptors on B cells, there is the potential for B-cell aplasia and hypogammaglobulinemia. Data on the degree and clinical significance of hypogammaglobulinemia are sparse. OBJECTIVES: We sought to evaluate hypogammaglobulinemia after CD19-targeted CAR-T therapy and risk factors for hypogammaglobulinemia, infections, and mortality. METHODS: We performed a retrospective evaluation of 579 patients receiving CD19-directed CAR-T therapy and evaluated demographics, hypogammaglobulinemia (IgG ≤600 mg/dL), infections prior to and after CAR-T therapy, and risk factors for hypogammaglobulinemia, infection, hospitalizations, and mortality. RESULTS: Patients had a mean age of 64 years and 64% were male. Prior to CAR-T therapy, 60% of patients had hypogammaglobulinemia, which increased to 91% post-CAR-T therapy. Mean IgG levels decreased from pre- to post-CAR-T therapy levels (587 to 362 mg/dL; P < .0001). Thirty-seven percent of patients developed a serious infection post-CAR-T therapy. Hypogammaglobulinemia prior to CAR-T therapy was associated with worsening hypogammaglobulinemia after CAR-T therapy. Hypogammaglobulinemia post CAR-T therapy was associated with an increased risk of serious infection following CAR-T therapy (incidence rate ratio: 2.7; 95% CI: 1.5-5.2; P = .002). Risk factors for mortality included mild hypogammaglobulinemia (400 mg/dL < IgG ≤ 600 mg/dL), infections ≤100 days post-CAR-T therapy, and hospitalizations for infections. Immunoglobulin replacement was associated with a decreased risk of mortality. CONCLUSIONS: We identified ∼90% of patients with hypogammaglobulinemia after CAR-T therapy. Hypogammaglobulinemia before CAR-T therapy was strongly predictive of worsening hypogammaglobulinemia after CAR-T therapy, which was associated with an increased risk of serious infection and mortality post CAR-T therapy. Increased immunological monitoring is needed to identify high-risk patients who may benefit from interventions to decrease morbidity and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgammaglobulinemiaAntigens, CD19Immunotherapy, AdoptiveInfectionsReceptors, Chimeric AntigenHematologic NeoplasmsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

CAR-T therapyCD19Hypogammaglobulinemiaimmunoglobulin replacement therapyinfectionrisk factorssecondary immune deficiency

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Medicine, Massachusetts General Hospital, Boston, Mass.
  • Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass.
  • Department of Population Medicine, Harvard Medical School, Boston, Mass; Harvard Pilgrim Health Care Institute, Boston, Mass.
  • Harvard Medical School, Boston, Mass; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Mass.
  • Harvard Medical School, Boston, Mass; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Mass.
  • Department of Medicine, University of Washington, Seattle, Wash; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Wash; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle,…

Förderung

  • NIAID NIH HHS
  • NIAID
  • American Academy of Allergy Asthma and Immunology

Zitieren

APA

Sutherland, N. M., Zhou, B., Zhang, L., Ong, M. S., Hong, J. S., Pak, A., Liu, K. J., Frigault, M. J., Maus, M. V., Hill, J. A., Reynolds, K., Walter, J. E., Camargo, C. A., & Barmettler, S. (2025). Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality. Journal of Allergy and Clinical Immunology, 155(2), 605-615. https://doi.org/10.1016/j.jaci.2024.10.021

Vancouver

Sutherland NM, Zhou B, Zhang L, Ong MS, Hong JS, Pak A, et al. Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality. Journal of Allergy and Clinical Immunology. 2025;155(2):605-615. doi:10.1016/j.jaci.2024.10.021

BibTeX
@article{Sutherland2025,
  author = {Sutherland, Natalia M and Zhou, Baijun and Zhang, Lingxiao and Ong, Mei-Sing and Hong, Joseph S and Pak, Andrew and Liu, Katherine J and Frigault, Matthew J and Maus, Marcela V and Hill, Joshua A and Reynolds, Kerry and Walter, Jolan E and Camargo, Carlos A and Barmettler, Sara},
  title = {Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  volume = {155},
  number = {2},
  pages = {605--615},
  doi = {10.1016/j.jaci.2024.10.021}
}
Kostenlos starten →